Towards Renewed Health Economic Simulation of Type 2 Diabetes: Risk Equations for First and Second Cardiovascular Events from Swedish Register Data

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Ahmad Kiadaliri, Aliasghar ^a,b,c   Gerdtham, Ulf G ^a,b   Nilsson, Peter ^a   Eliasson, Björn ^d   Gudbjörnsdottir, Soffia ^d   Carlsson, Katarina Steen ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CALIBRATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DISEASE REGISTRY; FEMALE; HAZARD RATIO; HEALTH ECONOMICS; HEART FAILURE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; SIMULATION; SMOKING; SWEDEN; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; CARDIOVASCULAR DISEASES; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; STROKE; SWEDEN;

EID: 84877328748     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062650     Document Type: Article

References (41)

1. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, et al. (2004) A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model. Diabetologia 47: 1747-1759.
2. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, et al. (1997) Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 20: 725-734.
3. Brown JB, Russell A, Chan W, Pedula K, Aickin M, (2000) The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 50 (Suppl 3):: S15-S46.
4. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, et al. (2004) The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 20 (Suppl 1):: S5-26.
5. Mueller E, Maxion-Bergemann S, Gultyaev D, Walzer S, Freemantle N, et al. (2006) Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model. Diabetes Technol Ther 8 (2):: 219-36.
6. American Diabetes Association Consensus Panel (2004) Guidelines for computer modeling of diabetes and its complications. Diabetes Care 27: 2262-65.
7. The Mount Hood 4 Modeling Group (2007) Computer modeling of diabetes and its complications. Diabetes Care 30: 1638-46.
8. Tarride JE, Hopkins R, Blackhouse G, Bowen JM, Bischof M, et al. (2010) A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics 28 (4):: 255-77.
9. Kannel WB, McGee DL, (1979) Diabetes and cardiovascular risk factors: the Framingham Study. Circulation 59: 8-13.
10. UK Prospective Diabetes Study Group (1991) UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 34: 877-90.
11. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (14):: 977-86.
12. van Dieren S, Beulens JW, Kengne AP, Peelen LM, Rutten GE, et al. (2012) Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart 98 (5):: 360-9.
13. Yeo WW, Yeo KR, (2001) Predicting CHD risk in patients with diabetes mellitus. Diabet Med 18: 341-344.
14. Caro JJ, Klittich WS, Raggio G, Kavanagh PL, O'Brien JA, et al. (2000) Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes. Clin Ther 22 (1):: 116-27.
15. Caro JJ, Salas M, Ward AJ, Raggio G, O'Brien JA, et al. (2003) Combination therapy for type 2 diabetes: what are the potential health and cost implications in Canada? Can J Diabetes 27 (1):: 33-41.
16. Ward AJ, Salas M, Caro JJ, Owens D, (2004) Health and economic impact of combining metformin with nateglinide to achieve glycemic control: comparison of the lifetime costs of complications in the UK. Cost Eff Resour Alloc 2 (1):: 2.
17. Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M, (2008) Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care 31 (4):: 714-719.
18. Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, et al. (2008) Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors. Diabetes Care 31: 2154-59.
19. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, et al. (2007) The Effect of Pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 49: 1772-80.
20. Palmer AJ, Sendi PP, Spinas GA, (2000) Applying some UK Prospective Diabetes Study results to Switzerland: the cost effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes. Schweiz MedWochenschr 130 (27-28):: 1034-40.
21. Tilden DP, Mariz S, O'Bryan-Tear G, Bottomley J, Diamantopoulos A, (2007) A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics 25 (1):: 39-54.
22. Glynn RJ, Buring JE, (1996) Ways of measuring rates of recurrent events. BMJ 312: 364-367.
23. Gudbjornsdottir S, Cederholm J, Nilsson PM, Eliasson B, (2003) The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care 26: 1270-1276.
24. Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, et al. (2004) IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 50: 166-174.
25. Sukor JA, Redmond SJ, Chan GS, Lovell NH, (2012) Signal quality measures for unsupervised blood pressure measurement. Physiol Meas 33 (3):: 465-86.
26. Prentice R, Williams B, Peterson A, (1981) On the regression analysis of multivariate failure time data. Biometrika 68: 373-379.
27. Hosmer DW, Lemeshow S (1999) Applied Survival Analysis. Regression Modeling of Time to Event Data. Wiley: New York.
28. Gould WW, (1993) Linear splines and piecewise linear functions. Stata Technical Bulletin 15: 13-17.
29. StataCorp (2011) Stata Statistical Software: Release 11. College Station, TX: StataCorp LP.
30. Harrell FE, Lee KL, Mark DB, (1996) Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15: 361-387.
31. D'Agostino RB, Nam BH (2004) Evaluation of the performance of survival analysis models: Discrimination and Calibration measures. In Handbook of Statistics, Survival Methods. Vol 23. Edited by Balakrishnan N, Rao CR. Amsterdam: Elsevier B.V.
32. Gronnesby JK, Borgan O, (1996) A method for checking regression models in survival analysis based on the risk score. Lifetime Data Anal 2: 315-328.
33. Gudbjörnsdottir S, Eeg-Olofsson K, Cederholm J, Zethelius B, Eliasson B, et al. (2009) Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR). Diabet Med 26: 53-60.
34. Donnan PT, Donnelly L, New JP, Morris AD, (2006) Derivation and validation of a prediction score for major coronary heart disease events in a U.K. type 2 diabetic population. Diabetes Care 29: 1231-1236.
35. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, et al. (2002) Risk of stroke in type 2 diabetes estimated by the UK prospective diabetes study risk engine. Stroke 33: 1776-1781.
36. Yang X, Ma RC, So WY, Kong AP, Ko GT, et al. (2008) Development and validation of a risk score for hospitalization for heart failure in patients with Type 2 Diabetes Mellitus. Cardiovasc Diabetol 7: 9.
37. Hayes AJ, Clarke P, Leal J, Alva ML, Coleman R, et al. (2011) An improved model to estimate lifetime health outcomes of patients with type 2 diabetes using 30-year follow-up data from the United Kingdom prospective diabetes study. Diabetologia 54 (Suppl 1):: S8.
38. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, et al. (2008) Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diabetes Care 31: 2038-2043.
39. Zethelius B, Eliasson B, Eeg-Olofsson K, Svensson AM, Gudbjornsdottir S, et al. (2011) A new model for 5-year risk of cardiovascular disease in type 2 diabetes, from Swedish national diabetes register. Diabetes Res Clin Pract 93: 276-84.
40. Elley CR, Robinson E, Kenealy T, Bramley D, Drury PL, (2010) Derivation and validation of a new cardiovascular risk score for people with type 2 diabetes: the New Zealand diabetes cohort study. Diabetes Care 33 (6):: 1347-52.
41. Ekström N, Schiöler L, Svensson AM, Eeg-Olofsson K, Miao Jonasson J, et al. (2012) Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open 2 (4):: e001076.